BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, December 22, 2025
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Deltagen Gains At Least $10M In Private Financing Commitment

April 7, 2003
By Aaron Lorenzo

Deltagen Gains At Least $10M In Private Financing Commitment

April 7, 2003
By Aaron Lorenzo

Orchid Brings In $16M Through Private Sale Of Preferred Stock

April 3, 2003
By Aaron Lorenzo

Orchid Brings In $16M Through Private Sale Of Preferred Stock

April 3, 2003
By Aaron Lorenzo

Viragen Secures $12M In Credit To Essentially Fund Operations

April 2, 2003
By Aaron Lorenzo

Viragen Secures $12M In Credit To Essentially Fund Operations

April 2, 2003
By Aaron Lorenzo

Synta Steps Out Of The Shadows With $75.3M Funding For Pipeline

March 31, 2003
By Aaron Lorenzo
On its website, Synta Pharmaceuticals Inc. bills itself as the newest 10-year-old pharma firm in Boston. (BioWorld Today)
Read More

Synta Steps Out Of The Shadows With $75.3M Funding For Pipeline

March 31, 2003
By Aaron Lorenzo
On its website, Synta Pharmaceuticals Inc. bills itself as the newest 10-year-old pharma firm in Boston. (BioWorld Today)
Read More

Telik Begins Registration Study Of TLK286 In Ovarian Cancer

March 28, 2003
By Aaron Lorenzo
Plans to push its lead compound into a Phase III trial has Telik Inc. beaming like a proud parent at a child's graduation. (BioWorld Today)
Read More

Telik Begins Registration Study Of TLK286 In Ovarian Cancer

March 28, 2003
By Aaron Lorenzo
Plans to push its lead compound into a Phase III trial has Telik Inc. beaming like a proud parent at a child's graduation. (BioWorld Today)
Read More
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 19, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 19, 2025.
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Illustration of brain with electrical activity background

    ABS-1230 controls seizures in KCNT1-driven severe epilepsy

    BioWorld Science
    Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing